# A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

> clinical trial · VERIFIED · 2026-06-23

Status: NOT_YET_RECRUITING · Sponsor: Glycyx Therapeutics · Condition: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

- Company: Glycyx Therapeutics
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT07662720

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.